- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02965768
Immune Effects of Low-dose Naltrexone in ME/CFS
August 30, 2022 updated by: Jarred Younger, University of Alabama at Birmingham
The Immune Effects of Low-dose Naltrexone in People With Myalgic Encephalopathy/Chronic Fatigue Syndrome (ME/CFS)
The main objective of this study is to test if naltrexone, when taken in low doses, has an anti-inflammatory effect that may be associated with positive clinical outcomes in people with chronic fatigue syndrome (CFS).
In part, the present study, is a continuation of prior work in which we showed that chronic fatigue symptoms are associated with immune activity, and that low-dose naltrexone might exert anti-inflammatory effects in fibromyalgia, which is thought to share some pathophysiological and clinical characteristics with CFS.
Study Overview
Study Type
Interventional
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama At Birmingham
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
1. Meet the 1994 Case Definition criteria for CFS (assessed through semi-structured interview and the DePaul University Fatigue Questionnaire):
Criteria:
- Severe chronic fatigue ≥6 consecutive months not due to ongoing exertion or other medical condition associated with fatigue;
- Fatigue interferes with daily activities and work;
- Reports ≥4 symptoms that started with or after the fatigue, from:
- Post-exertion malaise >24 hours
- Unrefreshing sleep
- Short-term memory or concentration impairment
- Muscle pain
- Joint pain without swelling or redness
- Headaches of a new type/pattern/severity
- Lymph node tenderness
- Frequent or recurring sore throat 3. CFS symptoms for ≥12 months 4. Participant completes daily self-report during the 4-week baseline period; 5. Able to attend UAB on all scheduled appointments
Exclusion Criteria:
- Blood draw contraindicated or otherwise not able to be performed
- High-sensitivity c-reactive protein (HS-CRP) ≥3 mg/L
- Erythrocyte sedimentation rate (ESR) >60 mm/hr
- Positive rheumatoid factor
- Positive anti-nuclear antibody (ANA)
- Levels of thyroid stimulating hormone or free thyroxine outside UAB lab reference values
- Diagnosed rheumatological or auto-immune condition
- Clotting disorder
- Use of blood thinning medication
- Oral temperature >100˚F at baseline
- Febrile illness or use of antibiotics in the 4 weeks before study commencement;
- Planned surgery or procedures during the study period, or operated on in the 4 weeks before study commencement
- Pregnant or planning on becoming pregnant within 6 months
- Regular use of any anti-inflammatory medication (such as aspirin, ibuprofen, naproxen)
- Known allergy or adverse effects following naltrexone or naloxone administration
- Opioid use (self-reported or positive on urine test)
- Significant psychological comorbidity that in the discretion of the investigator compromises study integrity and/or a baseline HADS depression subscale score of ≥16
- Current litigation or worker's compensation claim
- Current participation in another treatment trial
- Vaccinated in the 4 weeks before study commencement (vaccination during the study period is allowed as long as the drug is administered at least 4 weeks prior to a study blood draw).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: LDN arm
Naltrexone HCl 4.5mg (standard-dose) or 3.0mg (optional-dose) x24 weeks
|
4.5 mg Naltrexone HCl, p.o., nocte (standard-dose); 3.0 mg Naltrexone HCl, p.o., nocte (optional-dose);
Other Names:
|
Other: Placebo/LDN arm
Naltrexone HCl 4.5mg (standard-dose) or 3.0mg (optional-dose) Placebo Individuals will be switched between drugs as per approved schedule during the 24 weeks. |
4.5 mg Naltrexone HCl, p.o., nocte (standard-dose); 3.0 mg Naltrexone HCl, p.o., nocte (optional-dose);
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction in plasma inflammatory biomarkers
Time Frame: Four-week baseline; 12 weeks drug
|
Levels of plasma IL-1B, TNFa, IL6, IL12, and IL17 will be tested as the primary biomarkers of interest.
|
Four-week baseline; 12 weeks drug
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Durability of reduction in plasma inflammatory biomarkers
Time Frame: Baseline; 12 weeks drug; 24 weeks drug
|
Levels of plasma IL-1B, TNFa, IL6, IL12, and IL17 will be tested as the primary biomarkers of interest.
24 weeks vs 12 weeks drug.
|
Baseline; 12 weeks drug; 24 weeks drug
|
Reduction in self-reported fatigue
Time Frame: 12 weeks drug
|
Fatigue will be reported daily on a hand-held computer device.
|
12 weeks drug
|
Increase in physical function
Time Frame: 12 weeks drug
|
Physical function will be reported weekly on a Patient-Specific Functional Scale.
|
12 weeks drug
|
Reduction in self-reported symptoms of (i) depression, (ii) anxiety
Time Frame: 12 weeks drug
|
Symptoms of depression and anxiety will be reported weekly on a Hospital Anxiety and Depression Scale.
|
12 weeks drug
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2016
Primary Completion (Actual)
August 25, 2022
Study Completion (Actual)
August 25, 2022
Study Registration Dates
First Submitted
November 14, 2016
First Submitted That Met QC Criteria
November 16, 2016
First Posted (Estimate)
November 17, 2016
Study Record Updates
Last Update Posted (Actual)
September 2, 2022
Last Update Submitted That Met QC Criteria
August 30, 2022
Last Verified
August 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Central Nervous System Diseases
- Nervous System Diseases
- Virus Diseases
- Infections
- Disease
- Musculoskeletal Diseases
- Muscular Diseases
- Neuromuscular Diseases
- Encephalomyelitis
- Syndrome
- Fatigue
- Fatigue Syndrome, Chronic
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Sensory System Agents
- Narcotic Antagonists
- Alcohol Deterrents
- Naltrexone
Other Study ID Numbers
- F160525003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fatigue Syndrome, Chronic
-
Oslo University HospitalCompletedAdolescent Chronic Fatigue SyndromeNorway
-
Shanghai University of Traditional Chinese MedicineShanghai Yueyang Integrated Medicine HospitalRecruiting
-
Ho Cheol Shin, M.D., Ph.D.Green Cross Corporation; Ajou University School of Medicine; SymyooCompletedChronic Fatigue Syndrome | Idiopathic Chronic FatigueKorea, Republic of
-
AIM ImmunoTech Inc.Available
-
King Saud UniversityCompletedChronic Fatigue Syndrome (CFS)
-
Stony Brook UniversityCompletedChronic Fatigue Syndrome | Medically Unexplained Chronic FatigueUnited States
-
Centre Hospitalier Universitaire de Saint EtienneNot yet recruitingChronic Fatigue SyndromeFrance
-
Power Life Sciences Inc.Not yet recruitingChronic Fatigue SyndromeUnited States
-
Heilongjiang Quanle Pharmaceutical Co., Ltd.Not yet recruiting
-
King's College LondonSouth London and Maudsley NHS Foundation TrustNot yet recruiting
Clinical Trials on Naltrexone HCl
-
PfizerCompletedLow Back Pain | Chronic Pain | AnalgesiaUnited States
-
TakedaWithdrawnWeight Regain Post Bariatric SurgeryUnited States
-
PfizerCompleted
-
Alza Corporation, DE, USACompleted
-
USWM, LLC (dba US WorldMeds)National Institute on Drug Abuse (NIDA)Completed
-
Boston Children's HospitalCompletedNew Daily Persistent Headache (NDPH)United States
-
Weill Medical College of Cornell UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH)TerminatedProlonged Grief DisorderUnited States
-
Milton S. Hershey Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); The...CompletedInflammation | Crohn's DiseaseUnited States
-
Xhale AssuranceNational Institute on Drug Abuse (NIDA)Completed
-
Massachusetts General HospitalUnited States Department of DefenseCompletedADHD | Stimulant-Induced EuphoriaUnited States